Pasar al contenido principal

NUEVOS MODELOS PARA EL ESTUDIO DE LAS ALTERACIONES GENETICAS RECURRENTES Y RESISTENCIA A FARMACOS EN LA LEUCEMIA LINFATICA CRONICA.

RTI2018-094584-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  • Nadeu, Ferran
  • Massoni-Badosa, Ramon
  • Ruiz Gil, Sara
  • Marchese, Domenica, 1986-
  • López Bigas, Núria
  • Gut, Ivo Glynne
  • Heyn, Holger
  • Campo, Elias
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high-B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT., This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR-736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundació La Marató de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigación Biomédica en Red Cáncer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovación (PID2020-117185RB-I00 to X.S.P.), the Fundación Asociación Española Contra el Cáncer (FUNCAR-PRYGN211258SUÁR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5 × 1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya. This work was partially developed at the Center Esther Koplowitz (Barcelona, Spain).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia

  • López-Oreja, Irene
  • Gohr, André
  • Playa-Albinyana, Heribert
  • Giró, Ariadna
  • Arenas, Fabián
  • Higashi, Morihiro
  • Tripathi, Rupal
  • López-Guerra, Mónica
  • Irimia Martínez, Manuel
  • Aymerich, Marta
  • Valcárcel, J. (Juan)
  • Bonnal, Sophie
  • Colomer Pujol, Dolors
Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of patients with chronic lymphocytic leukemia (CLL) and are associated with poor prognosis, but their pathogenic mechanisms remain poorly understood. Using deep RNA-sequencing data from 298 CLL tumor samples and isogenic SF3B1 WT and K700E-mutated CLL cell lines, we characterize targets and pre-mRNA sequence features associated with the selection of cryptic 3' splice sites upon SF3B1 mutation, including an event in the MAP3K7 gene relevant for activation of NF-κB signaling. Using the H3B-8800 splicing modulator, we show, for the first time in CLL, cytotoxic effects in vitro in primary CLL samples and in SF3B1-mutated isogenic CLL cell lines, accompanied by major splicing changes and delayed leukemic infiltration in a CLL xenotransplant mouse model. H3B-8800 displayed preferential lethality towards SF3B1-mutated cells and synergism with the BCL2 inhibitor venetoclax, supporting the potential use of SF3B1 inhibitors as a novel therapeutic strategy in CLL., The work of the authors is supported by the Spanish Ministry of Science and Innovation through the Plan Estatal de Investigación Científica y Técnica y de Innovación (RTI2018-094584-B-I00; PID2021-123165OB-I00; BFU-2017-89308-P, PID2020-114630GB-I00) and was cofounded by the European Regional Development Fund (ERDF), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program ERC-AdG-LS2-670146 l, CERCA program from Generalitat de Catalunya, Centre of Excellence Severo Ochoa Award (CEX2020-001049) to the Centre for Genomic Regulation of the Barcelona Institute of Science and Technology, Centro de Investigación Biomédica en Cáncer (CIBERONC) (CB16/12/334), Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya (2017 SGR 1009; 2021 SGR-1294) and Asociación Española Contra el Cancer (AECC) (PRYGN223298VALC). We thank Elias Campo for sharing transcriptomics data from ICGC consortium and for reviewing the manuscript. We thank Suzanne Mays, Estefania Mancini, Malgorzata Rogalska, and Ferran Nadeu for their help and all the laboratory members from Juan Valcarcel’s group.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Challenges with approved targeted therapies against recurrent mutations in CLL: a place for new actionable targets

  • López-Oreja, Irene
  • Playa-Albinyana, Heribert
  • Arenas, Fabián
  • López-Guerra, Mónica
  • Colomer Pujol, Dolors
Chronic lymphocytic leukemia (CLL) is characterized by a high degree of genetic variability and interpatient heterogeneity. In the last decade, novel alterations have been described. Some of them impact on the prognosis and evolution of patients. The approval of BTK inhibitors, PI3K inhibitors and Bcl-2 inhibitors has drastically changed the treatment of patients with CLL. The effect of these new targeted therapies has been widely analyzed in TP53-mutated cases, but few data exist about the response of patients carrying other recurrent mutations. In this review, we describe the biological pathways recurrently altered in CLL that might have an impact on the response to these new therapies together with the possibility to use new actionable targets to optimize treatment responses., The group has been supported by the Spanish Ministry of Science and Innovation through the Plan Estatal de Investigación Científica y Técnica y de Innovación [RTI2018-094584-B-I00] and was cofounded by the European Regional Development Fund (ERDF) and the CERCA program from Generalitat de Catalunya, Centro de Investigación Biomédica en Cáncer (CIBERONC) and Generalitat de Catalunya [2017 SGR 1009].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy

  • Silkenstedt, Elisabeth
  • Arenas, Fabian
  • Colom-Sanmartí, Berta
  • Xargay-Torrent, Sílvia
  • Higashi, Morihiro
  • Giró, Ariadna
  • Rodriguez, Vanina
  • Fuentes, Patricia
  • Aulitzky, Walter E
  • van der Kuip, Heiko
  • Beà, Silvia
  • Toribio, María Luisa
  • Campo, Elías
  • López-Guerra, Mònica
  • Colomer, Dolors
The Author(s)., [Background]: NOTCH1 gene mutations in mantle cell lymphoma (MCL) have been described in about 5–10% of cases and are associated with significantly shorter survival rates. The present study aimed to investigate the biological impact of this mutation in MCL and its potential as a therapeutic target., [Methods]: Activation of Notch1 signaling upon ligand-stimulation and inhibitory effects of the monoclonal anti-Notch1 antibody OMP-52M51 in NOTCH1-mutated and -unmutated MCL cells were assessed by Western Blot and gene expression profiling. Effects of OMP-52M51 treatment on tumor cell migration and tumor angiogenesis were evaluated with chemotaxis and HUVEC tube formation assays. The expression of Delta-like ligand 4 (DLL4) in MCL lymph nodes was analyzed by immunofluorescence staining and confocal microscopy. A MCL mouse model was used to assess the activity of OMP-52M51 in vivo., [Results]: Notch1 expression can be effectively stimulated in NOTCH1-mutated Mino cells by DLL4, whereas in the NOTCH1-unmutated cell line JeKo-1, less effect was observed upon any ligand-stimulation. DLL4 was expressed by histiocytes in both, NOTCH1-mutated and –unmutated MCL lymph nodes. Treatment of NOTCH1-mutated MCL cells with the monoclonal anti-Notch1 antibody OMP-52M51 effectively prevented DLL4-dependent activation of Notch1 and suppressed the induction of numerous direct Notch target genes involved in lymphoid biology, lymphomagenesis and disease progression. Importantly, in lymph nodes from primary MCL cases with NOTCH1/2 mutations, we detected an upregulation of the same gene sets as observed in DLL4-stimulated Mino cells. Furthermore, DLL4 stimulation of NOTCH1-mutated Mino cells enhanced tumor cell migration and angiogenesis, which could be abolished by treatment with OMP-52M51. Importantly, the effects observed were specific for NOTCH1-mutated cells as they did not occur in the NOTCH1-wt cell line JeKo-1. Finally, we confirmed the potential activity of OMP-52M51 to inhibit DLL4-induced Notch1-Signaling in vivo in a xenograft mouse model of MCL., [Conclusion]: DLL4 effectively stimulates Notch1 signaling in NOTCH1-mutated MCL and is expressed by the microenvironment in MCL lymph nodes. Our results indicate that specific inhibition of the Notch1-ligand-receptor interaction might provide a therapeutic alternative for a subset of MCL patients., The study was supported by research funding from the Spanish Ministry of Economy and Competitiveness through the Plan Estatal de Investigación Científica y Técnica y de Innovación [MINECO], SAF15–67633-R and RTI2018–094584-B-I00 [to DC], SAF2016–75442-R [to MLT] and was cofunded by the European Regional Development Fund [ERDF] and the CERCA program from Generalitat de Catalunya, Centro de Investigación Biomédica en Cáncer [CIBERONC] [CB16/12/00334 and CB16/12/00225] and Generalitat de Catalunya Suport Grups de Recerca [2017 SGR 1009] and the Robert-Bosch-Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  • Nadeu, Ferran
  • Royo, Romina
  • Massoni-Badosa, Ramon
  • Playa-Albinyana, Heribert
  • Garcia-Torre, Beatriz
  • Duran-Ferrer, Martí
  • Dawson, Kevin J.
  • Kulis, Marta
  • Diaz-Navarro, Ander
  • Villamor, Neus
  • Melero, Juan L.
  • Chapaprieta, Vicente
  • Dueso-Barroso, Ana
  • Delgado, Julio
  • Moia, Riccardo
  • Ruiz-Gil, Sara
  • Marchese, Domenica
  • Giró, Ariadna
  • Verdaguer-Dot, Núria
  • Romo, Mónica
  • Clot, Guillem
  • Rozman, María
  • Frigola, Gerard
  • Rivas-Delgado, Alfredo
  • Baumann, Tycho
  • Alcoceba, Miguel
  • González, Marcos
  • Climent, Fina
  • Abrisqueta, Pau
  • Castellví, Josep
  • Bosch, Francesc
  • Aymerich, Marta
  • Enjuanes, Anna
  • Ruiz-Gaspà, Sílvia
  • López-Guillermo, Armando
  • Jares, Pedro
  • Beà, Silvia
  • Capella-Gutiérrez, Salvador
  • Gelpí, Josep Lluis
  • López-Bigas, Nuria
  • Torrents, David
  • Campbell, Peter J.
  • Gut, Ivo
  • Rossi, Davide
  • Gaidano, Gianluca
  • Puente, Xose S.
  • García-Roves, Pablo M.
  • Colomer, Dolors
  • Heyn, Holger
  • Maura, Francesco
  • Martín-Subero, José Ignacio
  • Campo, Elías
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high–B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT., This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40- 11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/ AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundació La Marató de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigación Biomédica en Red Cáncer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovación (PID2020-117185RB-I00 to X.S.P.), the Fundación Asociación Española Contra el Cáncer (FUNCAR-PRYGN211258SUÁR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5×1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Challenges with approved targeted therapies against recurrent mutations in CLL: a place for new actionable targets

  • López-Oreja, Irene
  • Playa-Albinyana, Heribert
  • Arenas, Fabián
  • López-Guerra, Mónica
  • Colomer Pujol, Dolors
Chronic lymphocytic leukemia (CLL) is characterized by a high degree of genetic variability and interpatient heterogeneity. In the last decade, novel alterations have been described. Some of them impact on the prognosis and evolution of patients. The approval of BTK inhibitors, PI3K inhibitors and Bcl-2 inhibitors has drastically changed the treatment of patients with CLL. The effect of these new targeted therapies has been widely analyzed in TP53-mutated cases, but few data exist about the response of patients carrying other recurrent mutations. In this review, we describe the biological pathways recurrently altered in CLL that might have an impact on the response to these new therapies together with the possibility to use new actionable targets to optimize treatment responses., The group has been supported by the Spanish Ministry of Science and Innovation through the Plan Estatal de Investigación Científica y Técnica y de Innovación [RTI2018-094584-B-I00] and was cofounded by the European Regional Development Fund (ERDF) and the CERCA program from Generalitat de Catalunya, Centro de Investigación Biomédica en Cáncer (CIBERONC) and Generalitat de Catalunya [2017 SGR 1009].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia

  • López-Oreja, Irene
  • Gohr, André
  • Playa-Albinyana, Heribert
  • Giró, Ariadna
  • Arenas, Fabián
  • Higashi, Morihiro
  • Tripathi, Rupal
  • López-Guerra, Mónica
  • Irimia Martínez, Manuel
  • Aymerich, Marta
  • Valcárcel, J. (Juan)
  • Bonnal, Sophie
  • Colomer Pujol, Dolors
Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of patients with chronic lymphocytic leukemia (CLL) and are associated with poor prognosis, but their pathogenic mechanisms remain poorly understood. Using deep RNA-sequencing data from 298 CLL tumor samples and isogenic SF3B1 WT and K700E-mutated CLL cell lines, we characterize targets and pre-mRNA sequence features associated with the selection of cryptic 3' splice sites upon SF3B1 mutation, including an event in the MAP3K7 gene relevant for activation of NF-κB signaling. Using the H3B-8800 splicing modulator, we show, for the first time in CLL, cytotoxic effects in vitro in primary CLL samples and in SF3B1-mutated isogenic CLL cell lines, accompanied by major splicing changes and delayed leukemic infiltration in a CLL xenotransplant mouse model. H3B-8800 displayed preferential lethality towards SF3B1-mutated cells and synergism with the BCL2 inhibitor venetoclax, supporting the potential use of SF3B1 inhibitors as a novel therapeutic strategy in CLL., The work of the authors is supported by the Spanish Ministry of Science and Innovation through the Plan Estatal de Investigación Científica y Técnica y de Innovación (RTI2018-094584-B-I00; PID2021-123165OB-I00; BFU-2017-89308-P, PID2020-114630GB-I00) and was cofounded by the European Regional Development Fund (ERDF), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program ERC-AdG-LS2-670146 l, CERCA program from Generalitat de Catalunya, Centre of Excellence Severo Ochoa Award (CEX2020-001049) to the Centre for Genomic Regulation of the Barcelona Institute of Science and Technology, Centro de Investigación Biomédica en Cáncer (CIBERONC) (CB16/12/334), Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya (2017 SGR 1009; 2021 SGR-1294) and Asociación Española Contra el Cancer (AECC) (PRYGN223298VALC). We thank Elias Campo for sharing transcriptomics data from ICGC consortium and for reviewing the manuscript. We thank Suzanne Mays, Estefania Mancini, Malgorzata Rogalska, and Ferran Nadeu for their help and all the laboratory members from Juan Valcarcel’s group.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

  • Nadeu, Ferran
  • Massoni-Badosa, Ramon
  • Ruiz Gil, Sara
  • Marchese, Domenica, 1986-
  • López Bigas, Núria
  • Gut, Ivo Glynne
  • Heyn, Holger
  • Campo, Elias
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high-B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT., This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR-736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundació La Marató de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigación Biomédica en Red Cáncer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovación (PID2020-117185RB-I00 to X.S.P.), the Fundación Asociación Española Contra el Cáncer (FUNCAR-PRYGN211258SUÁR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5 × 1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institució Catalana de Recerca i Estudis Avançats of the Generalitat de Catalunya. This work was partially developed at the Center Esther Koplowitz (Barcelona, Spain).